The primary therapeutic function of Xembify is commonly used to help with providing long-term antibody replacement therapy for individuals diagnosed with Primary Humoral Immunodeficiency (PI), a set of chronic, inherited conditions where the body cannot produce sufficient protective antibodies. This replacement contributes to essential immune system support for both adults and pediatric patients two years of age and older.

Xembify is used for managing conditions marked by a profound, congenital lack of functional antibodies, including Common Variable Immunodeficiency (CVID) and X-linked Agammaglobulinemia. The therapy may assist with addressing the measurable deficit of circulating Immunoglobulin G (IgG), which supports establishing a layer of immune support. The medicine is applied in addressing the symptom cluster of recurrent, unusually severe, and prolonged infections, such as pneumonia, sinusitis, and bronchitis.

“The treatment may assist with reducing the frequency and severity of these infectious episodes, which contributes to improved day-to-day comfort and helps ease the physical burden associated with ongoing infections.”

Beyond reducing acute illness, Xembify is commonly used to help with easing the long-term impact of recurrent, severe infection. The therapy supports the maintenance of functional stability and may assist with managing the long-term symptomatic consequences of recurrent infections, thereby supporting the patient’s sustained health and general functioning capacity.

Regulatory References

1. National Library of Medicine DailyMed Label

Official Eligibility and Non-Eligibility Rules

Regulatory documents define strict rules for who can and cannot use Xembify, establishing absolute non-eligibility and conditional use requirements for specific populations.

Age-Related and Condition-Specific Restrictions

The medicine is not indicated for children younger than two years of age, as safety and efficacy have not been established in this group. For patients over 65 years, the label advises that the medicine be administered at the minimum infusion rate practicable due to an increased risk of thrombosis.

Conditional Use is required for patients with certain medical conditions:

• Renal Risk: Patients with preexisting renal insufficiency or a predisposition to acute renal failure must have renal function assessed prior to the initial infusion and monitored thereafter.
• Thrombosis Risk: Patients with conditions such as hypercoagulable states, cardiovascular risk factors, or prolonged immobilization must receive the product at the minimum dose and infusion rate practicable.

Use in pregnant and breastfeeding women has not been studied, and therefore, its safety and capacity to affect reproduction or harm the fetus are unknown according to official labeling.

Interactions with other medicines and products

Xembify (immune globulin subcutaneous, human) contains antibodies that can interact with certain other medical products. The primary documented drug interactions relate to the potential effects on the immune response and laboratory test results.

Interactions with Vaccines

• Live Attenuated Virus Vaccines: The passive transfer of antibodies from Xembify may transiently interfere with the immune response to live attenuated virus vaccines, such as those for measles, mumps, rubella, and varicella (chickenpox). This interference could potentially reduce the effectiveness of the vaccine. It is essential to inform the prescribing physician or immunizing healthcare professional of recent therapy with Xembify before receiving any such vaccines, as specific timing and spacing recommendations may be necessary to ensure adequate vaccine protection.

Drug-Laboratory Test Interactions

• Serologic Testing: Because Xembify introduces a wide range of antibodies into the bloodstream, the passive transfer of these antibodies may confound or interfere with the results of certain serologic tests. Patients should ensure that all healthcare providers ordering blood or laboratory tests are aware they are receiving immune globulin therapy.

General Precaution

As with any prescription medicine, patients should always inform their healthcare provider about all prescription and non-prescription drugs, over-the-counter medicines, vitamins, and herbal products they are currently taking.

️ How Xembify Works

Xembify’s mechanism of action is one of passive immune replacement, utilizing Immunoglobulin G (IgG) to establish functional antibody-mediated activity. The effect is exerted through distinct, simultaneous mechanistic domains.

Molecular Neutralization and Pathogen Binding

The IgG molecules function as high-affinity ligands, directly binding to antigens and epitopes on external microbial threats. This molecular neutralization physically blocks the capacity of foreign agents to interact with host cells. This action leads to the physiological outcome of immediate functional presence of antibody-mediated activity systemically.

Opsonization and Innate Immune Clearance

The mechanism extends to the Fc Receptors (FcγR) on phagocytic cells and complement proteins. The binding of the IgG-antigen complex triggers opsonization, accelerating microbial uptake and destruction by the innate immune system, resulting in acceleration of microbial clearance.

Concentration-Driven Sustained Activity

Functional capacity requires maintaining a high and stable IgG trough level in the circulation to ensure continuous target saturation and threat neutralization. This sustained presence, which is concentration-dependent, is necessary to maintain a sustained state of antibody-mediated activity over time.

Administration and Dosage Guidelines for Xembify

Xembify is administered solely via subcutaneous infusion (SCIG) using an infusion pump. The dose and administration frequency are individualized based on the patient's clinical response and serum Immunoglobulin G (IgG) trough levels. It may be administered at regular intervals, ranging from daily up to every two weeks (biweekly).

Official Dosing Rules:

• Treatment-naïve patients (aged 2 years): Receive a loading dose of 150 mg/kg/day for five consecutive days, followed by a weekly maintenance dose of 150 mg/kg/week starting on Day 8.
• Switching from intravenous immune globulin (IVIG): The initial weekly dose (in grams) is calculated by multiplying the previous IVIG dose (in grams) by a dose adjustment factor of 1.37 and dividing by the number of weeks between IVIG doses. Treatment should begin one week after the last IVIG infusion.

Preparation and Procedure:

Prior to use, the vial(s) must be allowed to naturally reach room temperature; they must not be shaken or diluted. The solution should be visually inspected for discoloration or particulate matter and must not be used if cloudy or turbid. Using aseptic technique, the required volume is withdrawn into a sterile syringe. The infusion must be started within 8 hours of transfer from the vial.

Administration involves up to six infusion sites simultaneously (abdomen, thigh, upper arm, or hip), which must be rotated for each dose and separated by at least 2 inches (5 cm). The maximum volume per site for all ages is 25 mL. The maximum infusion rate for adults and children ge 10 years is le 35 mL/hr/infusion site; for children 2 to <10 years, the maximum rate is le 25 mL/hr/infusion site. Adequate hydration is advised for patients at risk of thrombosis before administration.

Research evidence / Overview of studies for Xembify

Evidence for Use in Primary Humoral Immunodeficiency (PI)

Clinical research for Xembify has primarily focused on conditions marked by Primary Humoral Immunodeficiency (PI), which includes inherited conditions like Common Variable Immunodeficiency (CVID). This evidence is relevant in trials assessing the need for long-term antibody replacement therapy for patients whose bodies cannot produce enough functional antibodies. The main goal of the pivotal trials was to see what patterns of serious infections were monitored in study participants.

Study Design and Main Outcomes Measured

The initial research was evaluated in open-label, single-arm Phase 3 and Phase 4 clinical trials. This means the trials did not use a concurrent placebo group. Instead, researchers compared the outcomes observed in the study populations to a pre-defined expected rate of infection based on past data. The core outcomes related to systemic or functional imbalance that were measured in these studies included the Annualized Rate of Serious Bacterial Infections (SBIs) per patient per year.

Studies monitored the rate of serious bacterial infections, which was observed in some studies to meet the regulatory threshold established for replacement therapies. Additionally, the studies reported how symptoms evolved in the observed populations, specifically reporting low annual rates of infection-related hospitalizations and fewer days of activity missed due to infection.

Study Context for Related Secondary Immunodeficiency

Research was studied for some instances of Secondary Immunodeficiency (SID), which is an acquired lack of antibodies often seen in adults with specific conditions like certain blood cancers. The evidence derived from these settings is limited, and findings for the use of this therapy in this context are still emerging.

Currently, research in SID is ongoing, including randomized, controlled Phase 3 clinical trials that are applied in studies examining adult patients who have low IgG levels related to their underlying cancer condition. Because the primary findings from these key randomized, controlled trials are not yet available, certainty for this indication remains low compared to the primary indication.

Understanding Long-Term Follow-up and Duration of Evidence

The follow-up durations were limited in the core pivotal studies for Xembify, typically observing patient responses over one year (52 weeks). While this timeframe provides insight into short-term changes and the observed maintenance of antibody levels, the long-term effects are not fully established. Data regarding the long-term stability of observed outcomes and whether the patterns related to infection rates continue to be monitored over many years of treatment are not fully established by the initial clinical trials.

How to Store and Dispose of Xembify

Xembify (immune globulin subcutaneous, human-klhw) must be stored and handled according to specific regulatory requirements to maintain its stability and integrity.

Storage Conditions

The product must initially be stored in the refrigerator at 2 C to 8 C (36 F to 46 F) until the expiration date. Alternatively, it may be stored at stable room temperature (up to 25 C or 77 F) for a single period of up to 6 months.

Handling and Disposal

Do not shake the vial. If the solution is cloudy, discolored, or contains particulates, it must be discarded. As a single-use product, partially used vials must be discarded. All used administration supplies, including needles and lines, must be disposed of in an appropriate sharps container according to local regulatory requirements.